Top

Published in:

01-12-2006

Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course

Authors: Chang Hwan Choi, M.D., Tae Il Kim, M.D., Byung Chang Kim, M.D., Sung Jae Shin, M.D., Sang Kil Lee, M.D., Won Ho Kim, M.D., Hyon Suk Kim, M.D.

Published in: Diseases of the Colon & Rectum | Issue 12/2006

Purpose

This study was designed to assess anti-Saccharomyces cerevisiae antibody positive rate in Behçet’s disease and intestinal Behçet’s disease and to evaluate whether anti-Saccharomyces cerevisiae antibody expression is associated with clinical findings at diagnosis and clinical course of intestinal Behçet’s disease.

Methods

One hundred six patients with intestinal Behçet’s disease, 30 patients with Behçet’s disease, and 45 healthy control subjects were included. Anti-Saccharomyces cerevisiae antibody was detected by indirect immunofluorescence assay. According to anti-Saccharomyces cerevisiae antibody expression, the various parameters at diagnosis, cumulative relapse rates, and cumulative probabilities of operation were analyzed.

Results

Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease, 3.3 percent in Behçet’s disease, and 8.8 percent in healthy control subjects. In patients with intestinal Behçet’s disease, age, gender, distribution of Behçet’s disease subtype, symptoms, laboratory tests, and colonoscopic findings at diagnosis were not different according to anti-Saccharomyces cerevisiae antibody expression. Cumulative probability of a first operation was significantly higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti-Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease: 44.8 and 17.2 percent at one year, and 53 and 24.3 percent at two years after diagnosis, respectively (P = 0.006). The number of patients who underwent two or more operations was higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti-Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease (21.3 vs. 8.5 percent). The cumulative relapse rates were not different between the two groups.

Conclusions

Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease. Clinical findings at diagnosis and cumulative relapse rates of intestinal Behçet’s disease were not found to be associated with anti-Saccharomyces cerevisiae antibody expression. However, patients with anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease were more likely to receive surgical treatment.

Behçet, H 1937Uber rezidivierende aphthose, durch ein Virus verursachte Geschwure am Auge und an den GenitalienDermatol Wschr10511521157

O’Duffy, JD, Carney, JA, Deodhar, S 1971Behçet’s disease. Report of 10 cases, 3 with new manifestationsAnn Intern Med75561570PubMed

Chajek, T, Fainaru, M 1975Behçet’s disease. Report of 41 cases and a review of the literatureMedicine54179196PubMedCrossRef

O’Duffy, JD 1994Behçet’s diseaseCurr Opin Rheumatol63943PubMedCrossRef

Kaklamani, VG, Vaiopoulos, G, Kaklamanis, PG 1998Behçet’s diseaseSemin Arthritis Rheum27197217PubMedCrossRef

Sakane, T, Takeno, M, Suzuki, N, Inaba, G 1999Behçet’s diseaseN Engl J Med34112841291PubMedCrossRef

Kasahara, Y, Tanaka, S, Nishino, M, Umemura, H, Shiraha, S, Kuyama, T 1981Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literatureDis Colon Rectum24103106PubMed

Yurdakul, S, Tuzuner, N, Yurdakul, I, Hamuryudan, V, Yazici, H 1996Gastrointestinal involvement in Behçet’s syndrome: a controlled studyAnn Rheum Dis55208210PubMed

Yazici, H, Barnes, CG 1991Practical treatment recommendations for pharmacotherapy of Behçet’s syndromeDrugs42796804PubMed

10.

Peeters, M, Joossens, S, Vermeire, S, Vlietinck, R, Bossuyt, X, Rutgeerts, P 2001Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseaseAm J Gastroenterol96730734PubMedCrossRef

11.

Saxon, A, Shanahan, F, Landers, C, Ganz, T, Targan, S 1990A distinct subset of antineutrophil anticytoplasmic antibodies is associated with inflammatory bowel diseaseJ Allergy Clin Immunol86202210PubMedCrossRef

12.

Choi, CH, Kim, WH, Kim, TI, et al. 2003Antineutrophil cytoplasmic antibody in patients with ulcerative colitis: relation to clinical courseGastroenterology124A216CrossRef

13.

Sendid, B, Colombel, JF, Jacquinot, PM, et al. 1996Specific antibody response to oligomannosidic epitopes in Crohn’s diseaseClin Diagn Lab Immunol3219226PubMed

14.

Ruemmele, FM, Targan, SR, Levy, G, Dubinski, M, Braun, J, Seidman, EG 1998Diagnostic accuracy of serological assays in pediatric inflammatory bowel diseaseGastroenterology115822829PubMedCrossRef

15.

Quinton, JF, Sendid, B, Reumaux, D, et al. 1998Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic roleGut42788791PubMedCrossRef

16.

Mizushima, Y, Inaba, G, Mimura, Y, Ono, S 1988Diagnostic criteria for Behçet’s disease in 1987, and guidelines for treating Behçet’s diseaseSaishin Igaku43 382391

17.

Lee, CR, Kim, WH, Cho, YS, et al. 2001Colonoscopic findings in intestinal Behçet’s diseaseInflamm Bowel Dis7243249PubMedCrossRef

18.

Malchow, H, Ewe, K, Brandes, JW 1984European Cooperative Crohn’s Disease Study (ECCDS): result of drug treatmentGastroenterology86249266PubMed

19.

Yao, T 1996New criteria for the diagnosis of Crohn’s diseaseI To Cho31451464

20.

Oken, MM, Creech, RH, Tormey, DC, et al. 1982Toxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol5649655PubMed

21.

Ketch, LL, Buerk, CA, Liechty, D 1980Surgical implications of Behçet’s diseaseArch Surg115759760PubMed

22.

Sayek, I, Aran, O, Uzunalimoglu, B, Hersek, E 1991Intestinal Behçet’s disease: surgical experience in seven casesHepatogastroenterology388183PubMed

23.

Tsukada, S, Yamazaki, T, Iyo, S, et al. 1964Neuro-Behçet’s syndrome: report of two cases and review of the literatureSaishin Igaku1915331541

24.

Lehner, T 1977Oral ulceration and Behçet’s syndromeGut18491511PubMed

25.

Shimizu, T, Ehrlich, GE, Inaba, G, et al. 1979Behçet’s disease (Behçet’s syndrome)Semin Arthritis Rheum8223260PubMedCrossRef

26.

Bayraktar, Y, Özaslan, E, Thiel, DH 2000Gastrointestinal manifestations of Behçet’s diseaseJ Clin Gastroenterol30144154PubMedCrossRef

27.

Baba, S, Maruta, M, Ando, K, Teramoto, T, Endo, I 1976Intestinal Behçet’s disease: report of five casesDis Colon Rectum19428440PubMed

28.

Zouboulis, CC, Kotter, I, Djawari, D, et al. 1997Epidemiological features of Adamantiades: Behçet’s disease in Germany and in EuropeYonsei Med J38411422PubMed

29.

Oshima, Y, Shimizu, T, Yokohari, R, et al. 1963Clinical studies on Behçet’s syndromeAnn Rheum Dis223645CrossRefPubMed

30.

Ha, HK, Lee, HJ, Yang, SK, et al. 1998Intestinal Behçet syndrome: CT features of patients with and patients without complicationsRadiology209449454PubMed

31.

Barclay, GR, McKenzie, H, Pennington, J, Parratt, D, Pennington, CR 1992The effect of dietary yeast on the activity of stable chronic Crohn’s diseaseScand J Gastroenterol27196200PubMed

32.

Seibold, F, Brandwein, S, Simpson, S, Elson, CO 1998pANCA represent a cross-reactivity to enteric bacterial antigensJ Clin Immunol1823153160CrossRef

33.

Rump, JA, Scholmerich, J, Gross, V, et al. 1990A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s diseaseImmunobiology181406413PubMed

34.

Cambridge, G, Rampton, DS, Stevens, TR, McCarthy, DA, Kamm, M, Leaker, B 1992Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic roleGut33668674PubMed

35.

Duerr, RH, Targan, SR, Landers, CJ, et al. 1992Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: Comparison with other colitides/diarrheal illnessesGastroenterology10015901596

36.

Sandborn, WJ, Loftus, EV, Colombel, JF, et al. 2001Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s DiseaseInflamm Bowel Dis7192201PubMedCrossRef

37.

Sandborn, WJ, Landers, CJ, Tremaine, WJ, et al. 1996Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot studyMayo Clin Proc71431436PubMedCrossRef

38.

Fleshner, PR, Vasiliauskas, EA, Kam, LY, et al. 2001High level perinuclear antineutrophil cytoplasmic antibody (p-ANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosisGut49671677PubMedCrossRef

39.

Main, J, McKenzie, H, Yeaman, GR, et al. 1988Antibody to Saccharomyces cerevisiae (baker’s yeast) Crohn’s diseaseBMJ29711051106PubMedCrossRef

40.

Sander, U, Kunze, I, Broker, M, Kunze, G 1998Humoral immune response to a 200-kDA glycoprotein antigen of Saccharomyces cerevisiae is common in manImmunol Lett61113117PubMedCrossRef

41.

Vasiliauskas, EA, Kam, LY, Karp, LC, et al. 2000Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristicsGut47487496PubMedCrossRef

42.

Reddy, KR, Colombel, JF, Poulain, D, et al. 2001Anti-Saccharomyces cerevisiae antibodies in autoimmune liver diseaseAm J Gastroenterol96252253PubMedCrossRef

43.

Muratori, P, Muratori, L, Guidi, M, et al. 2003Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseasesClin Exp Immunol132473476PubMedCrossRef

44.

Seibold, FF, Stich, O, Hufnagl, R, Kamil, S, Scheurlen, M 2001Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family studyScand J Gastroenterol36196201PubMed

45.

Behçet’s Disease Research Committee of Japan1974Behçet’s disease: guide to diagnosis of Behçet’s diseaseJpn J Ophthalmol18291294

46.

Wechsler, B, Davatchi, F, Mizushima, Y, et al. 1990Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s DiseaseLancet33510781080

47.

Kim, KJ, Yang, SK, Myung, SJ, et al. 2002Diagnostic value of colonoscopic findings in the differential diagnosis between Crohn’s disease and intestinal Behçet’s disease [abstract]Gastrointest Endosc55A263

48.

Greenstein, AJ, Janowitz, HD, Sachar, DB 1976The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patientsMedicine55401412PubMedCrossRef

49.

Matsuda, T, Tanaka, C, Imamura, Y 1999Behçet’s diseaseMed Postgrad37350361

50.

Lee, RG 1986The colitis of Behçet’s syndromeAm J Surg Pathol10888893PubMedCrossRef

Title: Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course
Authors: Chang Hwan Choi, M.D.
Tae Il Kim, M.D.
Byung Chang Kim, M.D.
Sung Jae Shin, M.D.
Sang Kil Lee, M.D.
Won Ho Kim, M.D.
Hyon Suk Kim, M.D.
Publication date: 01-12-2006
Publisher: Springer-Verlag
Published in: Diseases of the Colon & Rectum / Issue 12/2006
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI: https://doi.org/10.1007/s10350-006-0706-z

2024 ASCO Annual Meeting

Springer Medicine

Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course

Purpose

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2006

What is the Optimal Time of Surgical Intervention After an Acute Attack of Sigmoid Diverticulitis: Early or Late Elective Laparoscopic Resection?

Perianal Local Block for Stapled Anopexy

Fistulating Anal Crohn’s Disease: Results of Combined Surgical and Infliximab Treatment

Complete Closure of Cancer-Related Anovaginal and Anoperineal Fistulas in Locally Advanced Anal Canal Carcinomas by Upfront Intra-Arterial Chemotherapy Followed by Combined Radiochemotherapy: Report of Two Cases

Selected Abstracts

Impact of Surgery on the Development of Duodenal Cancer in Patients with Familial Adenomatous Polyposis